Fulvestrant Powder Cas No.129453-61-8
Khoom Source: Synthetic
Khoom Specification: Ntau dua lossis sib npaug li 98%
CAS Nr .: 129453-61-8
Test Method: HPLC
Cov khoom xyaw nquag: Fulvestrant
Cov yam ntxwv ntawm cov khoom: Dawb hmoov
Ntim Cov Khoom: 1kg / hnab; 25kg / nruas
Cia Lub Sij Hawm: Khaws ntawm 2-8℃deb ntawm lub teeb nyob rau hauv cov thawv kaw nruj nreem
Lub neej txee: 24 lub hlis
Khoom Description
Xi'an Tinoj qab haus huvHigh -Purity Fulvestrant Raw Material Powder
Peb lub tuam txhab tshwj xeeb hauv kev tsim cov qib siab -purity Fulvestrant raw khoom hmoov (CAS: 129453-61-8), nruj me ntsis ua raws li cov qauv cGMP. Purity tsis tu ncua Ntau dua lossis sib npaug li 99.5% (HPLC kuaj). Cov khoom lag luam yog cov hmoov dawb crystalline sib ntsib USP / EP cov qauv tshuaj pharmacopoeia, nrog kev tswj xyuas nruj rau cov hlau hnyav, cov kuab tshuaj seem, thiab cov txwv microbial. Tag nrho-txheej txheem kev tswj xyuas zoo siv HPLC-MS kom paub meej batch-to-batch sib xws. Txee lub neej yog 24 lub hlis thaum muab ntim rau hauv qhov tsaus ntuj ntawm 2-8 degree. Customized specifications (xws li ntawm 1g mus rau kilogram kom muaj nuj nqis) thiab ua tiav COA / MSDS cov ntaub ntawv muaj nyob rau raws li thoob ntiaj teb kev cai raws li txoj cai.
Cov khoom muaj nuj nqi
1). Raws li tus neeg saib xyuas kev kho tshuaj hormone rau kev kho cov tshuaj estrogen receptor- zoo (ER+) siab lossis mob qog noj ntshav metastatic, tshwj xeeb tshaj yog tom qab tsis ua haujlwm ntawm lwm yam kev kho mob endocrine.
2). Inhibits qog nqaij hlav qog noj ntshav los ntawm downregulating estrogen receptors (ER).
Cov khoomDaim ntawv thov
Kev siv tshuaj kho mob:
Kev kho mob cancer mis:Siv los kho ER + qib siab lossis mob qog noj ntshav metastatic, tshwj xeeb tshaj yog tom qab tsis ua haujlwm ntawm lwm yam kev kho mob endocrine.
Combination Therapy:Feem ntau siv nrog CDK4/6 inhibitors (piv txwv li, palbociclib, ribociclib) los txhim kho kev ua tau zoo.
Kev Tshawb Fawb Ua Ntej:
Hauv qee qhov kev sim, fulvestrant ua ke nrog cov neeg ua haujlwm tshiab (xws li, PROTAC cov tshuaj) tau pom tias muaj txiaj ntsig zoo dua.
Cov khoom Cov lus qhia
1). Feem ntau rau cov poj niam postmenopausal, tshwj xeeb tshaj yog cov neeg uas muaj mob qog noj ntshav hauv zos lossis metastatic mis.
2). Tej zaum kuj tseem siv tau rau cov poj niam premenopausal nyob rau qee qhov xwm txheej, tab sis yuav tsum tau siv tshuaj kho zes qe menyuam.
Mechanism ntawmAkev txiav txim
1). Nws ua haujlwm los ntawm cov txheej txheem hauv qab no:
Inhibits receptor dimerization: Txo cov tshuaj estrogen receptor kev ua.
Txo receptor nuclear translocation: txo qis receptor kev ua nyob rau hauv lub cell nucleus.
Accelerates receptor degradation: Txo cov qib intracellular los ntawm kev txhawb nqa cov tshuaj estrogen receptor tawg.
2). Distinctive nta:
Fulvestrant tsis muaj cov tshuaj estrogen receptor agonist kev ua haujlwm, yog li tsis txhob cuam tshuam ib feem ntawm agonist pom nrog tamoxifen.
Pharmacological teebmeem
Thawj Pharmacological Action:
Inhibits qog cell proliferation los ntawm downregulating estrogen receptors.
Hauv cov qauv mob qog noj ntshav, fulvestrant qhia txog kev tiv thaiv- qog nqaij hlav piv rau lossis zoo tshaj tamoxifen.
Pharmacokinetic yam ntxwv:
Fulvestrant feem ntau yog siv los ntawm kev txhaj tshuaj intramuscular, tso tawm qeeb hauv lub cev nrog cov teebmeem ntev txog ib hlis.
Cov tshuaj no feem ntau metabolized los ntawm lub siab, nrog cov metabolites tawm ntawm cov kua tsib thiab zis.
Cim npe nrov: fulvestrant hmoov cas no.129453-61-8, Tuam Tshoj fulvestrant hmoov cas no.129453-61-8 manufacturers, lwm tus, Hoobkas
You Might Also Like
Xa kev nug